Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-0.34%
-0.64%
-1.11%
+18.19%
BTAI
BioXcel Therapeutics
$3.11
Chart
$5.67 (-45.15%)
$1.6 (+94.38%)
$1.69 (+84.02%)
$0.6 (+418.33%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.34%
-0.64%
-1.11%
+18.19%
BTAI
BioXcel Therapeutics
Current Price
$3.11
Login to view BioXcel Therapeutics (BTAI) recommendation from the last 90 days from financial news and social media.
Chart
$5.67 (-45.15%)
$1.6 (+94.38%)
$1.69 (+84.02%)
$0.6 (+418.33%)
BTAI has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
High volatilty
BTAI Latest Analysis
BioXcel Drug Calms Agitation At Home For Schizophrenia Bipolar Patients. ) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial which demonstrated that BXCL501 had continued effects and consistent benefit .The trial in the home setting evaluated a 120 mcg dose of BXCL501 the company’.s proprietary sublingual film formulation of dexmedetomidine Igalmi for agitation associated with bipolar disorders or schizophrenia.Recently BioXcel a
Wed Sep 10, 2025
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data From SERENITY At-Home Study . (RTTNews) - BioXcel Therapeutics Inc. (BTAI) Wednesday announced positive topline exploratory efficacy data from the SERENITY At-Home Phase 3 study of BXCL501 the companys proprietary sublingual film formulation of dexmedetomidine IGALMI for treatment of agitation associat
Wed Sep 10, 2025
BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment. ) announced that its SERENITY At-Home Phase 3 trial of BXCL501—its sublingual dexmedetomidine film for acute agitation in bipolar disorder or schizophrenia—. The results show consistent symptom reduction across 2400 episodes. It will now support an FDA supplemental filing to expand Igalmi'.s label for at-home use in Q1 2026. Efficacy in institutional settings was already established in SERENITY I and II.
Wed Aug 27, 2025
BioXcel Stock Surges 19% In After-Hours Trading: What You Need To Know. ) experienced significant after-hours momentum jumping 19.09% to $6.24 in the after-hours trading session on Tuesday as investors got ready for the release of important clinical trial results.Check out the current price of BTAI stock here.The biopharmaceutical company announced it will host an investor call today at 8 a.m. ET to review topline results from its SERENITY At-Home Pivotal Phase 3 safety trial. The study evaluate
Wed Aug 27, 2025
BioXcel to host investor call on SERENITY At-Home trial results.
Tue Aug 26, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BTAI Stock trends
BTAI Stock performance
BTAI Stock analysis
BTAI investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings